Aastrom Biosciences Announces Strategic Change in Research and Development Programs to Focus on Dilated Cardiomyopathy and Other Rare Disease Indications
27 mars 2013 08h45 HE
|
Aastrom Biosciences, Inc.
Focus shifted to Phase 2b ixCELL-DCM clinical study and the development of ixmyelocel-T for dilated cardiomyopathy, an orphan drug indication.
Company to stop enrollment and end Phase 3...
Aastrom Biosciences Reports Fourth-Quarter and Year-End 2012 Financial Results
18 mars 2013 16h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., March 18, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
Aastrom to Host Fourth Quarter 2012 Investor Call on March 18, 2013
12 mars 2013 16h15 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., March 12, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Board of Directors Names Dominick C. Colangelo President and Chief Executive Officer
06 mars 2013 16h15 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., March 6, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Board of Directors Names Dan Orlando Interim CEO
12 déc. 2012 09h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Dec. 12, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom to Present at the 23rd Annual Oppenheimer Healthcare Conference
10 déc. 2012 09h05 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Dec. 10, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Board Member Dr. Harold C. Urschel of Baylor University Medical Center Passes Away
26 nov. 2012 09h05 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 26, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom to Present at Therapeutic Area Partnerships Meeting
20 nov. 2012 09h15 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 20, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Reports Third-Quarter and Nine-Month 2012 Financial Results
08 nov. 2012 16h05 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 8, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe...
Aastrom to Host Third Quarter 2012 Investor Call on November 8, 2012
05 nov. 2012 09h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 5, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...